Related Experiment Video
Updated: Jan 27, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for
Giandomenico Roviello1, Navid Sohbani2, Roberto Petrioli3
1Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.
Abstract:
The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.
Insights
Ramucirumab shows survival benefits as a second-line treatment for advanced hepatocellular carcinoma (HCC) in patients with high AFP levels. Further research is needed to identify predictive biomarkers for personalized HCC therapy.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Cancer angiogenesis pathways
- Vascular endothelial growth factor (VEGF) signaling
Background:
- Second-line treatment options for advanced HCC are limited, with a recent focus on therapies demonstrating survival benefits.
- Predictive biomarkers for guiding treatment selection in advanced HCC remain largely unavailable.
- The REACH-2 trial highlighted ramucirumab's efficacy in a specific HCC patient subgroup.
Purpose of the Study:
- To review current knowledge on HCC carcinogenesis and the VEGF/VEGFR-2 pathway.
- To discuss the clinical development of ramucirumab in advanced HCC.
- To critically assess previous trial gaps and propose modernizations for clinical trials and personalized HCC therapy.
Main Methods:
- Review of existing literature on HCC, VEGF/VEGFR-2 pathways, and ramucirumab clinical trials.
- Analysis of data from the REACH-2 trial regarding ramucirumab efficacy.
- Critical evaluation of a previous negative phase III trial in advanced HCC.
Main Results:
- Ramucirumab, a VEGFR-2 inhibitor, demonstrated overall survival superiority against placebo in the REACH-2 trial for second-line HCC treatment.
- This benefit was observed in patients with alpha-fetoprotein (AFP) levels greater than 400 ng/ml.
- The study identifies a need for predictive biomarkers to personalize advanced HCC treatment.
Conclusions:
- Ramucirumab represents a significant advancement in second-line treatment for a specific population of advanced HCC patients.
- Understanding HCC angiogenesis and VEGF/VEGFR-2 pathways is crucial for developing targeted therapies.
- Modernizing clinical trial designs and incorporating biomarker strategies are essential for advancing personalized medicine in advanced HCC.
Related Concept Videos
Gene Therapy
Group Therapy
Psychodynamic Therapy
Humanistic Therapy
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Couples Therapy
Core Principles and Techniques
Couples therapy often incorporates cognitive-behavioral principles to identify and modify negative...

